Sun Pharma gets 8 observations from USFDA for Halol facility

16 Dec 2019 Evaluate

United States Food and Drug Administration (USFDA) has conducted Good Manufacturing Practices (GMP) inspection of Sun Pharmaceutical Industries’ Halol facility in Gujarat from December 03 to 13, 2019. At the conclusion of the inspection, the agency issued a Form 483, with eight observations. The company is preparing the response to the observations, which will be submitted to the USFDA within 15 business days. The company is committed to addressing these observations promptly. The company remains committed to working closely with the USFDA and continues to enhance its GMP compliance on an ongoing basis.

Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.

Sun Pharma Inds. Share Price

1545.25 19.40 (1.27%)
14-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1545.25
Dr. Reddys Lab 5861.00
Cipla 1356.95
Zydus Lifesciences 984.75
Lupin 1635.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.